At ESHG, Affy Provides Update on CytoScan Filing Plans, Discusses Cancer Testing Market | GenomeWeb

NUREMBERG, Germany — An Affymetrix executive this week affirmed the company's intention to submit its CytoScan HD to the US Food and Drug Administration by the end of this year, and said that it will have the product certified as an in vitro diagnostic in Europe in the same time frame.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.